![[CytoReason in The Times of Israel] Swiss pharma firm Ferring, Israel’s CytoReason join to battle bowel disease](https://blog.ourcrowd.com/wp-content/uploads/2017/10/the-times-of-israel-NEW.jpg)
CytoReason, an Israeli startup that uses artificial intelligence to build digital models of the human immune system and diseases to speed up drug development, said Wednesday it will collaborate with Ferring Pharmaceuticals, a Swiss multinational biopharmaceutical company, to find new treatments for patients with inflammatory bowel disease (IBD). Read...
Read More![[CytoReason in Mobi Health News] Israeli startup CytoReason joins forces with Ferring Pharmaceuticals to find new IBD treatment](https://blog.ourcrowd.com/wp-content/uploads/2018/02/mobihealthnews.jpg)
Israeli startup CytoReason today announced a partnership with Swiss multinational, Ferring Pharmaceuticals, to establish new treatments for inflammatory bowel disease (IBD). Read...
Read More![[CytoReason in PR Newswire] CytoReason Announces Collaboration with Ferring to Identify Novel Therapeutic Targets in Inflammatory Bowel Disease Using AI Technology](https://blog.ourcrowd.com/wp-content/uploads/2017/09/PR_newswire.jpg)
TEL AVIV, Israel, May 19, 2021 /PRNewswire/ — CytoReason, an Israeli company developing a computational model of the human body for faster drug discovery and development, today announced a collaboration with Swiss multinational biopharmaceutical company, Ferring Pharmaceuticals, which aims to establish new treatment options for patients with inflammatory bowel disease (IBD). Read...
Read More
Scientists at pharmaceutical giant Pfizer have long understood that people with various autoimmune diseases often have elevated levels of a protein called CCR6, believed to play a part in a range of conditions from lupus to irritable bowel disorder. Read...
Read More![[CytoReason in Pharmaceutical Technology] CytoReason Q&A: moving beyond animal testing in drug research](https://blog.ourcrowd.com/wp-content/uploads/2021/05/pharmaceutical-technology.jpg)
While animal testing is the first step in the clinical development of any drug, animals often prove to be unreliable models for human disease. CytoReason CEO David Harel discusses the limitations of animal studies, and the potential that alternative methods hold for the future of drug research and development. Read...
Read More
